The research driven pharmaceutical industry, represented by EFPIA, strives to improve human health and wellbeing. It is scientifically proven that climate change will adversely impact human health . Therefore, understanding the relationship between people, health and the environment is critical to ensuring
the pharmaceutical industry, along with other stakeholders, plays an active role in decarbonization.

Our mission is to create a collaborative environment that enables EFPIA member companies to innovate, discover, develop, and deliver new therapies and
vaccines for people across Europe.

Reducing the environmental impact of medicinal products development and manufacturing is an important area of low carbon innovation and pollution control. Changes to products their supply chains and manufacturing processes to reduce the Global Warming Potential (GWP) and/or impact on the environment can be achieved through innovation.

We believe that innovations will help us reduce the greenhouse gas (carbon dioxide, methane, nitrous oxide, hydrofluorocarbons, perfluorocarbons, and
sulphur hexafluoride) emissions from our company’s productions and supply chains.
Our member companies are mitigating climate change by specifically addressing the need for increased energy efficiency and lowered energy intensity across our value chains.